News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma AB (publ) issues new shares

March 24, 2014

PledPharma AB
Company Announcement

PledPharma AB (publ) issues new shares

Stockholm, 2014-03-24 17:35 CET (GLOBE NEWSWIRE) -- 
The pharmaceutical company PledPharma proposes a rights issue that can provide
the company with up to 20.25 million SEK. The proposal will be tabled at an EGM
in conjunction with the AGM on April 8. The positive data from the first part
of PLIANT study resulted in an adjustment of the dose in the remaining study in
order to further optimize the positive effects of PledOx®. As a consequence the
number of patients will be increased, which will be financed by proposed rights

As expected, the results from the first part of the PLIANT study showed that
PledOx® was well tolerated by the patients treated with FOLFOX chemotherapy.
Treatment with FOLFOX often causes severe painful sensory disorders known as
neuropathies. These severe side-effects did not occur in patients that were
pre-treated with PledOx. The lower dose of PledOx also indicated a reduction of
severe white blood cell-related side effects. According to these data, the
lower dose of PledOx seems to give the better effect. PledPharma has therefore
applied to the regulatory authorities for reduction of the higher dose of 10
μmol/kg to 5 μmol/kg while keeping the lower dose at 2 μmol/kg. 

This change in dose means that the full number (i.e. 42) of randomized patients
on the new dose must be included for the statistical evaluation, which results
in an expansion of the study and an extension of the trial period. Patients
treated with the new dose will, however, replace the majority of patients that
otherwise should have been treated with the 10 μmol/kg dose. 

“The study is fully up and running and patients are recruited as expected, says
CEO Jacques Näsström. To date 18 patients have been included in the study and
some additional 20 patients are identified for participation. Our current
estimation is that all patients from all participating countries in Europe and
the U.S. will be included in the study by the end of 2014 and overall
(top-line) results should be present towards the end of the first quarter of
2015” ends Näsström. 

PledPharma’s proposed rights issue can provide the company with up to
approximately 20.25 million SEK before the issue costs that are low. The rights
issue is carried out with a simplified procedure without producing a
prospectus. PledPharma will, however, produce a short information folder for
the rights issue, which will be distributed to all registered shareholders.
Reference will be made to the newly published annual report for 2013 and the
interim report for January-March 2014, which will be available on April 25. 

Subscription commitments corresponding to at least respective owners pro rata
share have been received from Staffan Persson, Peter Lindell, Carl Rosvall,
Thomas Bill, B&E Participation, Anders Ström and all of the company's board of
directors and management. The subscription commitments represent more than 50%
of the rights issue. No compensation for the subscription commitments has been
issued. The subscription commitments are not secured by advance payment or any
other security. The remainder of the issue is not guaranteed or otherwise

The company will shortly issue the notice summoning the extraordinary general
meeting that shall decide on the rights issue. This meeting will be held on
April 8, 2013 at 16:00 after the AGM. The notice is also available on the
company website 

Issue terms:

  -- The right to subscribe for one (1) new share for every thirteen (13)
     existing shares, resulting in 1,687,314 of new shares upon full
     subscription (equivalent to a dilution of approximately 7%)
  -- Price per share: 12 SEK 

Process & schedule:

Extraordinary General Meeting, April 8, 2014 at 16:00

Last day of trading in PledPharma shares with the right to receive subscription
rights, April 14, 2014 

First day of trading in PledPharma shares without right to receive subscription
rights, April 15, 2014 

Record date for participation in the share issue, April 17, 2014

Subscription period, 25 April to 9 May 2014

Trading in subscription rights, 25 April to 6 May 2014

First day of trading of the new shares is expected during week 24 (9-13 of

Issuer agent in connection with the rights issue is Sedermera Fondkomission.
Erik Penser Bankaktiebolag is the company's Certified Adviser. 

For further information, please contact:

Jacques Näsström, CEO

+46 737 13 09 79

Michaela Gertz, CFO

+46 709 26 17 75

About PledPharma

PledPharma is a Swedish pharmaceutical company that develops new therapies for
the treatment of life threatening diseases related to oxidative stress. The
initial objective is to develop a drug, PledOx®, which reduces severe
side-effects associated with chemotherapy. The current market for supportive
cancer care is some USD 10 billion. PledPharma also evaluates an existing
medicines possibility to reduce the damage that occurs on the heart muscle when
patients suffer from acute myocardial infarction. In addition to these
projects, the company is also evaluating opportunities of using our technology
platform in additional areas where there is a significant unmet medical need.
PledPharma has the potential to offer patients valuable and unique treatments
for serious life-threatening diseases where there is an opportunity fast
registration in the US through "breakthrough therapy" designation. This means
that the company has the potential to offer shareholders a good return on their
investment. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik
Penser Bankaktiebolag is the Certified Adviser. For further information, please



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10